{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:28:05Z","timestamp":1781177285539,"version":"3.54.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>Type 1 diabetes mellitus (T1DM) is an autoimmune disease that results in the destruction of insulin-producing pancreatic beta cells. The incidence and prevalence of T1DM are increasing, making this one of the most common diseases of childhood. The disease is associated with significant morbidity and mortality with patients experiencing reduced quality of life and decreased life expectancy compared with the general population. Patients become dependent on exogenous insulin which has been the primary treatment since its first clinical use over 100 years ago. Although there have been advancements in glucose monitoring technology and insulin delivery devices, most patients fail to meet glycemic targets. Research has therefore focused on different treatment options to delay or prevent disease progression. Monoclonal antibodies have previously been utilized to suppress the immune response following an organ transplant and were subsequently studied for their ability to treat autoimmune diseases. Teplizumab, a monoclonal antibody (manufactured by Provention Bio and marketed as Tzield), was recently approved by the Food and Drug Administration as the first preventative treatment for T1DM. The approval came after a 3-decade history of research and development. This article provides an overview of the discovery and mechanism of action of teplizumab, as well as the clinical trials that led to its approval.<\/jats:p>","DOI":"10.1097\/crd.0000000000000563","type":"journal-article","created":{"date-parts":[[2023,5,10]],"date-time":"2023-05-10T04:13:38Z","timestamp":1683692018000},"page":"572-576","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Teplizumab Therapy to Delay the Onset of Type 1 Diabetes"],"prefix":"10.1097","volume":"32","author":[{"given":"Joel","family":"Novograd","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Medical College\/Westchester Medical Center, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,5,9]]},"reference":[{"key":"R1-20250619","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S2213-8587(22)00218-2","article-title":"International diabetes federation diabetes atlas type 1 diabetes in adults special interest group. global incidence, prevalence, and mortality of type 1 diabetes in 2021 with projection to 2040: a modelling study.","volume":"10","author":"Gregory","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R3-20250619","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.3390\/ijms22126403","article-title":"Role of insulin in health and disease: an update.","volume":"22","author":"Rahman","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R4-20250619","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1056\/NEJMra0808284","article-title":"Genetics of type 1A diabetes.","volume":"360","author":"Concannon","year":"2009","journal-title":"N Engl J Med"},{"key":"R5-20250619","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.2337\/dc15-1419","article-title":"Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the endocrine society, and the American Diabetes Association.","volume":"38","author":"Insel","year":"2015","journal-title":"Diabetes Care"},{"key":"R6-20250619","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.2337\/dc22-S002","article-title":"2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022.","volume":"45","year":"2022","journal-title":"Diabetes Care"},{"key":"R7-20250619","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0140-6736(18)31506-X","article-title":"Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study.","volume":"392","author":"Rawshani","year":"2018","journal-title":"Lancet"},{"key":"R8-20250619","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1007\/s00125-022-05659-9","article-title":"Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts.","volume":"65","author":"Ruiz","year":"2022","journal-title":"Diabetologia"},{"key":"R9-20250619","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3389\/fendo.2018.00613","article-title":"The discovery of insulin: an important milestone in the history of medicine.","volume":"9","author":"Vecchio","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R11-20250619","first-page":"1","article-title":"Recent advances in immune-based therapies for type 1 diabetes.","author":"Smigoc Schweiger","year":"2022","journal-title":"Horm Res Paediatr"},{"key":"R12-20250619","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/S2213-8587(22)00351-5","article-title":"FDA approves teplizumab: a milestone in type 1 diabetes.","volume":"11","author":"Hirsch","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R14-20250619","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1902226","article-title":"An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes.","volume":"381","author":"Herold","year":"2019","journal-title":"N Engl J Med"},{"key":"R15-20250619","doi-asserted-by":"crossref","first-page":"28827","DOI":"10.1074\/jbc.R400012200","article-title":"T cell receptor signaling: beyond complex complexes.","volume":"279","author":"Huang","year":"2004","journal-title":"J Biol Chem"},{"key":"R16-20250619","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1146\/annurev.iy.06.040188.003213","article-title":"The T cell receptor\/CD3 complex: a dynamic protein ensemble.","volume":"6","author":"Clevers","year":"1988","journal-title":"Annu Rev Immunol"},{"key":"R17-20250619","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1021\/acs.biochem.9b00707","article-title":"Anti-CD3 antibody for the prevention of type 1 diabetes: a story of perseverance.","volume":"58","author":"Gaglia","year":"2019","journal-title":"Biochemistry"},{"key":"R18-20250619","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/00007890-198112000-00018","article-title":"Treatment of acute renal allograft rejection with OKT3 monoclonal antibody.","volume":"32","author":"Cosimi","year":"1981","journal-title":"Transplantation"},{"key":"R19-20250619","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome.","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"R20-20250619","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/eji.1830250603","article-title":"Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects.","volume":"25","author":"Vossen","year":"1995","journal-title":"Eur J Immunol"},{"key":"R21-20250619","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1172\/JCI16090","article-title":"Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).","volume":"111","author":"Herold","year":"2003","journal-title":"J Clin Invest"},{"key":"R22-20250619","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.4049\/jimmunol.148.9.2756","article-title":"Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression.","volume":"148","author":"Woodle","year":"1992","journal-title":"J Immunol"},{"key":"R23-20250619","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/imt-2016-0049","article-title":"Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside.","volume":"8","author":"Kuhn","year":"2016","journal-title":"Immunotherapy"},{"key":"R24-20250619","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0041-1345(98)00278-4","article-title":"Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience.","volume":"30","author":"Woodle","year":"1998","journal-title":"Transplant Proc"},{"key":"R25-20250619","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/00007890-199457110-00001","article-title":"A non-activating \u201chumanized\u201d anti-CD3 monoclonal antibody retains immunosuppressive properties in vivo.","volume":"57","author":"Alegre","year":"1994","journal-title":"Transplantation"},{"key":"R26-20250619","doi-asserted-by":"crossref","first-page":"eaai7793","DOI":"10.1126\/sciimmunol.aai7793","article-title":"Partial exhaustion of CD8 T cells and clinical response to teplizumab in new-onset type 1 diabetes.","volume":"1","author":"Long","year":"2016","journal-title":"Sci Immunol"},{"key":"R27-20250619","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3389\/fimmu.2015.00310","article-title":"Inhibitory receptors beyond T cell exhaustion.","volume":"6","author":"Fuertes Marraco","year":"2015","journal-title":"Front Immunol"},{"key":"R28-20250619","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.4049\/jimmunol.1100713","article-title":"Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells.","volume":"187","author":"Penaranda","year":"2011","journal-title":"J Immunol"},{"key":"R29-20250619","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.2337\/db13-0345","article-title":"Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.","volume":"62","author":"Herold","year":"2013","journal-title":"Diabetes"},{"key":"R30-20250619","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1056\/NEJMoa012864","article-title":"Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.","volume":"346","author":"Herold","year":"2002","journal-title":"N Engl J Med"},{"key":"R31-20250619","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2337\/diabetes.54.6.1763","article-title":"A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.","volume":"54","author":"Herold","year":"2005","journal-title":"Diabetes"},{"key":"R32-20250619","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1093\/ajhp\/zxac244","article-title":"Anti-CD3 monoclonal antibodies for the prevention and treatment of type 1 diabetes: a literature review.","volume":"79","author":"LeFevre","year":"2022","journal-title":"Am J Health Syst Pharm"},{"key":"R33-20250619","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.clim.2013.05.001","article-title":"Anti-CD3 clinical trials in type 1 diabetes mellitus.","volume":"149","author":"Daifotis","year":"2013","journal-title":"Clin Immunol"},{"key":"R34-20250619","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/eji.201545708","article-title":"Changes in T-cell subsets identify responders to FcR-nonbinding anti-CD3 mAb (teplizumab) in patients with type 1 diabetes.","volume":"46","author":"Tooley","year":"2016","journal-title":"Eur J Immunol"},{"key":"R39-20250619","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/pedi.12996","article-title":"Changing costs of type 1 diabetes care among US children and adolescents.","volume":"21","author":"Crossen","year":"2020","journal-title":"Pediatr Diabetes"},{"key":"R40-20250619","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s40273-020-00962-y","article-title":"Cost effectiveness of teplizumab for prevention of type 1 diabetes among different target patient groups.","volume":"38","author":"Mital","year":"2020","journal-title":"PharmacoEcon"},{"key":"R41-20250619","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S2213-8587(22)00390-4","article-title":"Teplizumab approval for type 1 diabetes in the USA.","volume":"11","author":"Evans-Molina","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R42-20250619","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S2213-8587(22)00391-6","article-title":"Teplizumab approval for type 1 diabetes in the USA.","volume":"11","author":"Kordonouri","year":"2023","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T16:04:02Z","timestamp":1750349042000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,9]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000000563","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,9]]}}}